Generics and API maker Ranbaxy has opened a plant in Casablanca, Morocco in a bid to strengthen its foothold in the “increasingly important” North African drugs market.
GSK will launch an apprenticeship programme later this year to train young people in a range of industry disciplines, including manufacturing, R&D and supply chain management.
Pierrel Research is close to inking a takeover deal with Swiss R&D firm monoBIOTECH that it says will help shape“the new paradigm of the drug discovery and development process.”
The head of Pfizer's virtual clinical trial has defended the project after its initial failure to recruit patients raised questions about its viability.
Celerion and Ricera Biosciences have launched a new joint venture to provide a cost-cutting one-stop-shop solution for companies developing and commercialising biosimilars.
Pharma companies must become more involved in building patient communities through social media if they want to see a successful trial recruitment process according to Patient Nucleus founder Jamie Blackburn.
Quintiles has added to its commercial services capabilities in the Middle East and North Africa (MENA) region through an agreement with UAE-based Dayarn Pharma.
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
Sponsors want CROs to join the debate on quality management in clinical research says the Avoca Group, which has invited contractors to sign up to its recently established industry consortium.
BASF has hiked its prices for ethanolamines just days after asking the European Commission to review measures designed to stop US exporters selling the compound to manufacturers in Europe at less than cost.
Russia’s trial sector has largely recovered from the ‘crisis’ created by revision of approval system in 2010, but regulators are still taking too long to OK studies says industry group ACTO.
HUYA Bioscience says it will strengthen bonds between Chinese drug innovators and worldwide developers and through its new partnership with the Tianjin Institute of Pharmaceutical Research (TIPR).
Outsourcing is a gamble for the industry that needs a closer collaborative approach if pharma firms want a successful performance, according to new research.
